Difesa Capital Management’s Starling Oncology Warrant STLNW Stock Holding History

Difesa Capital Management’s Portfolio STLNW Stock Details STLNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-82,749	Closed	-$3.72K	–	27
2023 Q2	$3.72K	Sell	82,749 -33,226	-29%	-$1.83K	0.01%	34
2023 Q1	$11K	Hold	115,975	–	–	0.01%	128
2022 Q4	$12.8K	Hold	115,975	–	–	0.01%	127
2022 Q3	$59K	Hold	115,975	–	–	0.03%	117
2022 Q2	$58K	Sell	115,975 -9,025	-7%	-$8.3K	0.03%	129
2022 Q1	$144K	Hold	125,000	–	–	0.07%	129
2021 Q4	$86K	Buy	+125,000	New	+$155K	0.06%	133

Other funds holding STLNW

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Difesa Capital Management's STLNW Position: Q3 2023 in Review

Difesa Capital Management sold out of Starling Oncology Warrant (STLNW) in Q3 2023, closing a stake of 82,749 shares — an estimated $3.72K sold.

Difesa Capital Management first reported a position in STLNW in Q4 2021 and held it in 7 quarters. The position peaked at $144K in Q1 2022. 14 funds tracked by Wall St. Rank hold STLNW as of Q3 2023.

Difesa Capital Management reported no remaining Starling Oncology Warrant position as of Q3 2023 after selling out during the quarter.
Difesa Capital Management sold 82,749 Starling Oncology Warrant shares in Q3 2023, an estimated $3.72K.
Difesa Capital Management first reported a position in Starling Oncology Warrant in Q4 2021 and held it in 7 quarters.
Difesa Capital Management's Starling Oncology Warrant position peaked at $144K in Q1 2022.
14 funds tracked by Wall St. Rank held Starling Oncology Warrant as of Q3 2023.

Based on Difesa Capital Management's 13F filing for Q3 2023.